What to Look for in AbbVie’s Oncology Portfolio in 2019

Margaret Patrick
What to Look for in AbbVie’s Oncology Portfolio in 2019

According to Evaluate Pharma’s World Preview 2019 report, AbbVie and Johnson & Johnson’s (JNJ) Imbruvica is expected to become the fifth-highest-selling pharmaceutical product in the world by 2024.